Advertisement
Australia markets open in 1 hour 34 minutes
  • ALL ORDS

    7,831.90
    -100.10 (-1.26%)
     
  • AUD/USD

    0.6530
    +0.0051 (+0.78%)
     
  • ASX 200

    7,569.90
    -94.20 (-1.23%)
     
  • OIL

    79.11
    +0.11 (+0.14%)
     
  • GOLD

    2,330.40
    +19.40 (+0.84%)
     
  • Bitcoin AUD

    88,550.30
    -3,946.77 (-4.27%)
     
  • CMC Crypto 200

    1,274.67
    -64.40 (-4.81%)
     

Bioxyne Full Year 2023 Earnings: EPS: AU$0.002

Bioxyne (ASX:BXN) Full Year 2023 Results

Key Financial Results

  • Revenue: AU$5.34m (up 115% from FY 2022).

  • Net loss: AU$1.94m (loss widened by AU$1.70m from FY 2022).

  • EPS: AU$0.002.

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Bioxyne shares are down 8.3% from a week ago.

Risk Analysis

You still need to take note of risks, for example - Bioxyne has 4 warning signs (and 2 which make us uncomfortable) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.